With increasing interest in studying biological systems across spatial scales--from centimetres down to nanometres--histology continues to be the gold standard for tissue imaging at cellular resolution, providing an essential bridge between macroscopic and nanoscopic analysis. However, its inherently destructive and two-dimensional nature limits its ability to capture the full three-dimensional complexity of tissue architecture. Here we show that phase-contrast X-ray microscopy can enable three-dimensional virtual histology with subcellular resolution. This technique provides direct quantification of electron density without restrictive assumptions, allowing for direct characterisation of cellular nuclei in a standard laboratory setting. By combining high spatial resolution and soft tissue contrast, with automated segmentation of cell nuclei, we demonstrated virtual H&E staining using machine learning-based style transfer, yielding volumetric datasets compatible with existing histopathological analysis tools. Furthermore, by integrating electron density and the sensitivity to nanometric features of the dark field contrast channel, we achieve stain-free, high-content imaging capable of distinguishing nuclei and extracellular matrix.

Despite continued advances in oncology, cancer remains a leading cause of global mortality, highlighting the need for diagnostic and prognostic tools that are both accurate and interpretable. Unimodal approaches often fail to capture the biological and clinical complexity of tumors. In this study, we present a suite of task-specific AI models that leverage CT imaging, multi-omics profiles, and structured clinical data to address distinct challenges in segmentation, classification, and prognosis. We developed three independent models across large public datasets. Task 1 applied a 3D U-Net to segment pancreatic tumors from CT scans, achieving a Dice Similarity Coefficient (DSC) of 0.7062. Task 2 employed a hierarchical ensemble of omics-based classifiers to distinguish tumor from normal tissue and classify six major cancer types with 98.67% accuracy. Task 3 benchmarked classical machine learning models on clinical data for prognosis prediction across three cancers (LIHC, KIRC, STAD), achieving strong performance (e.g., C-index of 0.820 in KIRC, AUC of 0.978 in LIHC). Across all tasks, explainable AI methods such as SHAP and attention-based visualization enabled transparent interpretation of model outputs. These results demonstrate the value of tailored, modality-aware models and underscore the clinical potential of applying such tailored AI systems for precision oncology. Technical FoundationsO_LISegmentation (Task 1): A custom 3D U-Net was trained using the Task07_Pancreas dataset from the Medical Segmentation Decathlon (MSD). CT images were preprocessed with MONAI-based pipelines, resampled to (64, 96, 96) voxels, and intensity-windowed to HU ranges of -100 to 240. C_LIO_LIClassification (Task 2): Multi-omics data from TCGA--including gene expression, methylation, miRNA, CNV, and mutation profiles--were log-transformed and normalized. Five modality-specific LightGBM classifiers generated meta-features for a late-fusion ensemble. Stratified 5-fold cross-validation was used for evaluation. C_LIO_LIPrognosis (Task 3): Clinical variables from TCGA were curated and imputed (median/mode), with high-missing-rate columns removed. Survival models (e.g., Cox-PH, Random Forest, XGBoost) were trained with early stopping. No omics or imaging data were used in this task. C_LIO_LIInterpretability: SHAP values were computed for all tree-based models, and attention-based overlays were used in imaging tasks to visualize salient regions. C_LI

PSMA PET/CT imaging has been increasingly utilized in the management of patients with metastatic prostate cancer (mPCa). Imaging biomarkers derived from PSMA PET may provide improved prognostication and prediction of treatment response for mPCa patients. This study investigates a novel deep learning-derived imaging biomarker framework for outcome prediction using multi-modal PSMA PET/CT and clinical features. A single institution cohort of 99 mPCa patients with 396 lesions was evaluated. Imaging features were extracted from cropped lesion areas and combined with clinical variables including body mass index, ECOG performance status, prostate specific antigen (PSA) level, Gleason score, and treatments received. The PSA progression-free survival (PFS) model was trained using a ResNet architecture with a Cox proportional hazards loss function using five-fold cross-validation. Performance was assessed using concordance index (C-index) and Kaplan-Meier survival analysis. Among evaluated model architectures, the ResNet-18 backbone offered the best performance. The multi-modal deep learning framework achieved a 5-fold cross-validation C-index ranging from 0.75 to 0.94, outperforming models incorporating imaging only (0.70-0.89) and clinical features only (0.53-0.65). Kaplan-Meir survival analysis performed on the deep learning-derived predictions demonstrated clear risk stratification, with a median PSA progression free survival (PFS) of 19.7 months in the high-risk group and 26 months in the low-risk group (P < 0.001). Deep learning-derived imaging biomarker based on PSMA PET/CT can effectively predict PSA PFS for mPCa patients. Further clinical validation in prospective cohorts is warranted.

Neurodegeneration and cognitive impairment are commonly reported in Alzheimers disease (AD); however, their multivariate links are not well understood. To map the multivariate relationships between whole brain neurodegenerative (WBN) markers, global cognition, and clinical severity in the AD continuum, we developed the explainable artificial intelligence (AI) methods, validated on semi-simulated data, and applied the outperforming method systematically to large-scale experimental data (N=1,756). The outperforming explainable AI method showed robust performance in predicting cognition from regional WBN markers and identified the ground-truth simulated dominant brain regions contributing to cognition. This method also showed excellent performance on experimental data and identified several prominent WBN regions hierarchically and simultaneously associated with cognitive declines across the AD continuum. These multivariate regional features also correlated with clinical severity, suggesting their clinical relevance. Overall, this study innovatively mapped the multivariate regional WBN-cognitive-clinical severity relationships in the AD continuum, thereby significantly advancing AD-relevant neurobiological pathways.

Echocardiography traditionally requires experienced operators to select and interpret clips from specific viewing angles. Clinical decision-making is therefore limited for handheld cardiac ultrasound (HCU), which is often collected by novice users. In this study, we developed a view-agnostic deep learning framework to estimate left ventricular ejection fraction (LVEF), patient age, and patient sex from any of several views containing the left ventricle. Model performance was: (1) consistently strong across retrospective transthoracic echocardiography (TTE) datasets; (2) comparable between prospective HCU versus TTE (625 patients; LVEF r2 0.80 vs. 0.86, LVEF [> or [&le;]40%] AUC 0.981 vs. 0.993, age r2 0.85 vs. 0.87, sex classification AUC 0.985 vs. 0.996); (3) comparable between prospective HCU data collected by experts versus novice users (100 patients; LVEF r2 0.78 vs. 0.66, LVEF AUC 0.982 vs. 0.966). This approach may broaden the clinical utility of echocardiography by lessening the need for user expertise in image acquisition.

BackgroundPositron Emission Tomography (PET) myocardial perfusion imaging (MPI) is a powerful tool for predicting coronary artery disease (CAD). Coronary artery calcium (CAC) provides incremental risk stratification to PET-MPI and enhances diagnostic accuracy. We assessed additive value of CAC score, derived from PET/CT attenuation maps to stress TPD results using the novel 18F-flurpiridaz tracer in detecting significant CAD. Methods and ResultsPatients from 18F-flurpiridaz phase III clinical trial who underwent PET/CT MPI with 18F-flurpiridaz tracer, had available CT attenuation correction (CTAC) scans for CAC scoring, and underwent invasive coronary angiography (ICA) within a 6-month period between 2011 and 2013, were included. Total perfusion deficit (TPD) was quantified automatically, and CAC scores from CTAC scans were assessed using artificial intelligence (AI)-derived segmentation and manual scoring. Obstructive CAD was defined as [&ge;]50% stenosis in Left Main (LM) artery, or 70% or more stenosis in any of the other major epicardial vessels. Prediction performance for CAD was assessed by comparing the area under receiver operating characteristic curve (AUC) for stress TPD alone and in combination with CAC score. Among 498 patients (72% males, median age 63 years) 30.1% had CAD. Incorporating CAC score resulted in a greater AUC: manual scoring (AUC=0.87, 95% Confidence Interval [CI] 0.34-0.90; p=0.015) and AI-based scoring (AUC=0.88, 95%CI 0.85-0.90; p=0.002) compared to stress TPD alone (AUC 0.84, 95% CI 0.80-0.92). ConclusionsCombining automatically derived TPD and CAC score enhances 18F-flurpiridaz PET MPI accuracy in detecting significant CAD, offering a method that can be routinely used with PET/CT scanners without additional scanning or technologist time. CONDENSED ABSTRACTO_ST_ABSBackgroundC_ST_ABSWe assessed the added value of CAC score from hybrid PET/CT CTAC scans combined with stress TPD for detecting significant CAD using novel 18F-flurpiridaz tracer Methods and resultsPatients from the 18F-flurpiridaz phase III clinical trial (n=498, 72% male, median age 63) who underwent PET/CT MPI and ICA within 6-months were included. TPD was quantified automatically, and CAC scores were assessed by AI and manual methods. Adding CAC score to TPD improved AUC for manual (0.87) and AI-based (0.88) scoring versus TPD alone (0.84). ConclusionsCombining TPD and CAC score enhances 18F-flurpiridaz PET MPI accuracy for CAD detection O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=110 SRC="FIGDIR/small/25330013v1_ufig1.gif" ALT="Figure 1"> View larger version (37K): [email protected]@ba93d1org.highwire.dtl.DTLVardef@13eabd9org.highwire.dtl.DTLVardef@1845505_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGraphical Abstract.C_FLOATNO Overview of the study design. C_FIG

Lacunes, which are small fluid-filled cavities in the brain, are signs of cerebral small vessel disease and have been clinically associated with various neurodegenerative and cerebrovascular diseases. Hence, accurate detection of lacunes is crucial and is one of the initial steps for the precise diagnosis of these diseases. However, developing a robust and consistently reliable method for detecting lacunes is challenging because of the heterogeneity in their appearance, contrast, shape, and size. To address the above challenges, in this study, we propose a lacune detection method using the Segment Anything Model (SAM), guided by point prompts from a candidate prompt generator. The prompt generator initially detects potential lacunes with a high sensitivity using a composite loss function. The SAM model selects true lacunes by delineating their characteristics from mimics such as the sulcus and enlarged perivascular spaces, imitating the clinicians strategy of examining the potential lacunes along all three axes. False positives were further reduced by adaptive thresholds based on the region-wise prevalence of lacunes. We evaluated our method on two diverse, multi-centric MRI datasets, VALDO and ISLES, comprising only FLAIR sequences. Despite diverse imaging conditions and significant variations in slice thickness (0.5-6 mm), our method achieved sensitivities of 84% and 92%, with average false positive rates of 0.05 and 0.06 per slice in ISLES and VALDO datasets respectively. The proposed method outperformed the state-of-the-art methods, demonstrating its effectiveness in lacune detection and quantification.

Generative AI models have demonstrated strong potential in radiology report generation, but their clinical adoption depends on physician trust. In this study, we conducted a radiology-focused Turing test to evaluate how well attendings and residents distinguish AI-generated reports from those written by radiologists, and how their confidence and decision time reflect trust. we developed an integrated web-based platform comprising two core modules: Report Generation and Report Evaluation. Using the web-based platform, eight participants evaluated 48 anonymized X-ray cases, each paired with two reports from three comparison groups: radiologist vs. AI model 1, radiologist vs. AI model 2, and AI model 1 vs. AI model 2. Participants selected the AI-generated report, rated their confidence, and indicated report preference. Attendings outperformed residents in identifying AI-generated reports (49.9% vs. 41.1%) and exhibited longer decision times, suggesting more deliberate judgment. Both groups took more time when both reports were AI-generated. Our findings highlight the role of clinical experience in AI acceptance and the need for design strategies that foster trust in clinical applications. The project page of the evaluation platform is available at: https://zachatalay89.github.io/Labsite.

PurposeWe report on a deep learning-based approach to the segmentation of geographic atrophy (GA) in patients with advanced age-related macular degeneration (AMD). MethodThree-dimensional (3D) optical coherence tomography (OCT) data was collected from two instruments at two different retina practices. This totaled 367 and 348 volumes, respectively, of routinely collected clinical data. For all data, the accuracy of a 3D-to-2D segmentation model was assessed relative to ground-truth manual labeling. ResultsDice Similarity Scores (DSC) averaged 0.824 and 0.826 for each data set. Correlations (r2) between manual and automated areas were 0.883 and 0.906, respectively. The inclusion of near Infra-red imagery as an additional information channel to the algorithm did not notably improve performance. ConclusionAccurate assessment of GA in real-world clinical OCT data can be achieved using deep learning. In the advent of therapeutics to slow the rate of GA progression, reliable, automated assessment is a clinical objective and this work validates one such method.

Background and aimsAcute pancreatitis (AP) is a common gastrointestinal disease with rising global incidence. While most cases are mild, severe AP (SAP) carries high mortality. Early and accurate severity prediction is crucial for optimal management. However, existing severity prediction models, such as BISAP and mCTSI, have modest accuracy and often rely on data unavailable at admission. This study proposes a deep learning (DL) model to predict AP severity using abdominal contrast-enhanced CT (CECT) scans acquired within 24 hours of admission. MethodsWe collected 10,130 studies from 8,335 patients across a multi-site U.S. health system. The model was trained in two stages: (1) self-supervised pretraining on large-scale unlabeled CT studies and (2) fine-tuning on 550 labeled studies. Performance was evaluated against mCTSI and BISAP on a hold-out internal test set (n=100 patients) and externally validated on a Hungarian AP registry (n=518 patients). ResultsOn the internal test set, the model achieved AUROCs of 0.888 (95% CI: 0.800-0.960) for SAP and 0.888 (95% CI: 0.819-0.946) for mild AP (MAP), outperforming mCTSI (p = 0.002). External validation showed robust AUROCs of 0.887 (95% CI: 0.825-0.941) for SAP and 0.858 (95% CI: 0.826-0.888) for MAP, surpassing mCTSI (p = 0.024) and BISAP (p = 0.002). Retrospective simulation suggested the models potential to support admission triage and serve as a second reader during CECT interpretation. ConclusionsThe proposed DL model outperformed standard scoring systems for AP severity prediction, generalized well to external data, and shows promise for providing early clinical decision support and improving resource allocation.